Abstract
MK-208 is a guanidinothiazole derivative reported to be a potent H2 blocker devoid of antiandrogenic activity. Its potency and duration of action, in inhibiting pentagastrinstimulated gastric secretion in man, was evaluated in this double-blind, five-way crossover trial. Ten healthy male volunteers received single oral doses of placebo, cimetidine 300 mg, and MK-208 5, 10, and 20 mg. A continuous intravenous infusion of pentagastrin (1 μg/kg/hr) was given 2–4 and 5–7 hr after each oral dose. Gastric contents were continuously aspirated and volumes and acid content determined every 30 min. Plasma levels for MK-208 and cimetidine were monitored over the 7 hr of the study. Cimetidine and all doses of MK-208 significantly inhibited gastric acid secretion in the initial 2–4 hr; however, 10- and 20-mg doses of MK-208 were significantly more potent than cimetidine. In the 5- to 7-hr period, cimetidine 300 mg was not different from placebo, while MK-208 in all doses studied continued to significantly suppress gastric secretion. Plasma levels for MK-208 showed dose-related increments. The results suggest that: (1) MK-208 is a potent inhibitor of gastric secretion in man, in a dose-related fashion at the doses tested; (2) under the study conditions, 5 mg MK-208 was equipotent to 300 mg cimetidine but with greater duration of action, extending at least 7 hr; and (3) these data suggest a future role for this new agent in therapy for acid-peptic disease in man.
Similar content being viewed by others
References
Black JW, Duncan WAM, Durant CJ, Ganellin CR, Parsons EM: Definition and antagonism of histamine H2 receptors. Nature 236:385, 1972
Takeda M, Takage T, Maeno H: Effect of a new potent H2 blocker, 3-({[2-diaminomethylene)amino]-4-thiazolyl}methyl)thio-N 2-sulfamoylpropionamidine (YM-11170), on gastric secretion, ulcer formation, and weight of male accessory sex organs in rats. Arzneim Forsch 32:734–737, 1982
Takage T, Takeda M, Maeno H: Effect of a new potent H2 blocker, 3-({[2-diaminomethylene)amino]-4-thiazolyl}methyl)thio-N 2-sulfamoylpropionamidine (YM-11170), on gastric secretion induced by histamine and food in conscious dogs. Arch Int Pharmacodyn Ther 256:49–58, 1982
Pendleton RG, Torchiana ML, Chung C, Cook P, Wiese S, Clineschmidt BV: Studies on MK-208 (YM-11170) a new slowly dissociable H2-receptor antagonist. Arch Int Pharmacodyn Ther 266:4–16, 1983
Smith JL, Chremos AN, Gamal M, Graham DY: Gastric antisecretory effects in man of a novel H2-receptor inhibitor 3-({[2-diaminomethylene)amino]-4-thiazolyl}methyl)thio-N 2-sulfamoylpropionamidine (MK-208). Clin Pharm Ther 33:216, 1983
Moore EW, Scarlata RW: The determination of gastric acidity by the glass electrode. Gastroenterology 40:178–188, 1965
Fleitman J, Torosian G, Perrin JP: Improved high-power liquid chromatographic assay for cimetidine using ranitidine as an internal standard. J Chromatogr 229:255–258, 1982
Cochran WO, Cox GM: Experimental Design. New York, John Wiley & Sons, 1957
Snedecor GW, Cochran WG: Statistical Methods, 6th ed. Ames, Iowa, Iowa State University Press, 1967
Bodemar GW, Norlander B, Walan A: Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinet 6:306–315, 1981
Brater DC, Peters MN, Eshelman FN, Richardson CT: Clinical comparison of cimetidine and rantidine. Clin Pharm Ther 32:484–489, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McCallum, R.W., Chremos, A.N., Kuljian, B. et al. MK-208, a novel histamine H2-receptor inhibitor with prolonged antisecretory effect. Digest Dis Sci 30, 1139–1144 (1985). https://doi.org/10.1007/BF01314047
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01314047